Updates on neoadjuvant therapy in borderline resectable pancreatic cancer / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
;
(12): 206-209, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-466282
ABSTRACT
Borderline resectable pancreatic cancer (BRPC),characterized by low resectability rate and high postoperative recurrence rate,is a special kind of pancreatic cancer between resectable type and nonresectable one.Currently,the efficacy of neoadjuvant therapy for BRPC has become a hot topic in the field of pancreatic cancer.Although neoadjuvant therapy plays a critical role in obviously improving the R0 resectability rate and survival status of BRPC patients,the normalized therapeutic regimen has not been established.In this article,we overviewed the recent progress on the neoadjuvant therapy in treating BRPC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Hepatobiliary Surgery
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS